Category: Articles

Somerset, NJ – November 10, 2004 – The Institute of Packaging Professionals (IoPP) has recognized MedPointe’s ASTELIN Ready-SprayTM with an AmeriStar Award for excellence in consumer product package design in the pharmaceutical/drug category. Ronald Jaketic, Manager of Engineering Projects for MedPointe, accepted the award on behalf of MedPointe at the PACK EXPO International Show 2004 on November […]

Total Wallace Rx Promotional Efforts to Exceed 300 Sales Representatives; Innovex to Provide Sales Force Recruitment and Training Cranbury, NJ and Parsippany, NJ – January 14, 2002 – MedPointe Inc. and its Wallace Pharmaceuticals Division announced today that they have hired Innovex, a unit of Quintiles Transnational Corp. (NASDAQ: QTRN), to recruit and provide training support […]

Backed by Investment Firms Carlyle and Cypress, Pharmaceutical Executives Set to Build Specialty Healthcare Products Company Short Hills, NJ – May 8, 2001 – MedPointe Capital Partners, backed by private equity firms The Carlyle Group and The Cypress Group, announced this morning that it has entered into a definitive agreement to purchase the healthcare business of […]

Backed by Investment Firms Carlyle and Cypress, Pharmaceutical Executives Create MedPointe Inc. and Complete the Acquisition of Carter-Wallace and its Healthcare Business Cranbury, NJ – October 1, 2001 – A group of healthcare executives, backed by two leading private equity firms, announced today that it has completed the $408-million acquisition of the Healthcare Business and corporate […]

Clinical Data Published in Leading Medical Journal as Fall Allergy Season Begins Somerset, NJ – August 16, 2004 – ASTELIN® Nasal Spray provided effective symptom relief for patients with moderate-to-severe seasonal allergic rhinitis who had an unsatisfactory response to treatment with Allegra® (fexofenadine hydrochloride), according to a clinical study published in the August issue of Annals of Allergy, […]

Somerset, NJ and Rochester, NY – December 7, 2004 – MedPointe Pharmaceuticals announced today that its expanded sales force will now have sole responsibility for promoting MedPointe’s OPTIVAR® (azelastine hydrochloride ophthalmic solution 0.05%) to the ophthalmic/eye-care community starting January 1, 2005. Bausch & Lomb, a global leader in eye health, had provided sales support for OPTIVAR after […]

Purchase Strengthens MedPointe’s Allergy Franchise, Leverages Its Sales Force Somerset, NJ – April 29, 2003 – MedPointe Inc. announced that it has completed the acquisition of all U.S. and Canadian rights to Optivar® (azelastine hydrochloride), a prescription-only treatment for itching of the eye associated with allergic conjunctivitis in adults and children ages three and older. Comprised of […]

MedPointe strives to be a progressive company that adopts best practices in all that it does, from the development of new formulations and products to the harnessing of new manufacturing and information technologies to the hiring and professional development of its colleagues. In all of these endeavors, we maintain the highest ethical principles throughout all […]

Beth P. Hecht Executive Vice President, General Counsel and Secretary  Beth P. Hecht, Executive Vice President, General Counsel and Secretary of MedPointe, has more than 15 years of legal and corporate experience with pharmaceutical and high technology clients in the areas of mergers, acquisitions, divestitures, commercial transactions, litigation management, intellectual property counseling and securities reporting […]

  Paul R. Edick President & Chief Executive Officer; Board Director As President and Chief Executive Officer of MedPointe Pharmaceuticals, Paul Edick has assembled over the last twenty-eight years an outstanding track record of success in leading pharmaceutical organizations. Mr. Edick joined MedPointe in 2002 as President of its Wallace Pharmaceuticals division. Shortly thereafter, he […]